| Nov 11 |
Altimmune names Greg Weaver as CFO
|
| Nov 11 |
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Nov 11 |
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
|
| Nov 7 |
Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide
|
| Nov 7 |
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
|
| Nov 6 |
Altimmune to Participate at Two Upcoming Investor Conferences
|
| Nov 4 |
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
|
| Oct 28 |
Regulatory And Clinical Catalysts Ahead For Altimmune
|
| Oct 15 |
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
|
| Oct 2 |
Consider Buying Potential Takeover Target Altimmune
|
